» Articles » PMID: 32555717

Near-infrared Photoimmunotherapy is Effective Treatment for Colorectal Cancer in Orthotopic Nude-mouse Models

Overview
Journal PLoS One
Date 2020 Jun 20
PMID 32555717
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Photoimmunotherapy (PIT) employs the use of a near-infrared (NIR) laser to activate an antibody conjugated to a NIR-activatable dye to induce cancer cell death. PIT has shown to be effective in a number of studies, however, there are no data on its use in colorectal cancer in an orthotopic model.

Methods: Humanized anti-CEA antibody (M5A) was conjugated to NIR-activatable IRDye700DX (M5A-700). PIT was validated in vitro with a colon cancer cell-line, using a laser intensity of either 4 J/cm2, 8 J/cm2, or 16 J/cm2. Orthotopic colon cancer mouse models were established by surgical implantation of LS174T tumor fragments onto the cecum. M5A-700 was administered and PIT was performed 24 hours later using a 690 nm laser. Repeat PIT was performed after 7 days in one group. Control mice received laser treatment only.

Results: In vitro PIT demonstrated tumor cell death in a laser intensity dose-dependent fashion. In orthotopic models, control mice demonstrated persistent tumor growth. Mice that underwent PIT one time had tumor growth arrested for one week, after which re-growth occurred. The group that received repeated PIT exposure had persistent inhibition of tumor growth.

Conclusion: PIT arrests tumor growth in colon cancer orthotopic nude-mouse models. Repeated PIT arrests colon cancer growth for a longer period of time. PIT may be a useful therapy in the future as an adjunct to surgical resection or as primary therapy to suppress tumor progression.

Citing Articles

Experimental Murine Models for Colorectal Cancer Research.

Neto I, Rocha J, Gaspar M, Reis C Cancers (Basel). 2023; 15(9).

PMID: 37174036 PMC: 10177088. DOI: 10.3390/cancers15092570.


Near infrared photoimmunotherapy of cancer; possible clinical applications.

Wakiyama H, Kato T, Furusawa A, Choyke P, Kobayashi H Nanophotonics. 2022; 10(12):3135-3151.

PMID: 36405499 PMC: 9646249. DOI: 10.1515/nanoph-2021-0119.


Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.

Wei D, Qi J, Hamblin M, Wen X, Jiang X, Yang H Theranostics. 2022; 12(16):7108-7131.

PMID: 36276636 PMC: 9576624. DOI: 10.7150/thno.74820.


The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

Turner M, Lwin T, Amirfakhri S, Nishino H, Hoffman R, Yazaki P Biomolecules. 2021; 11(12).

PMID: 34944463 PMC: 8699160. DOI: 10.3390/biom11121819.


Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L Int J Nanomedicine. 2021; 16:2337-2356.

PMID: 33790553 PMC: 7997558. DOI: 10.2147/IJN.S297631.

References
1.
DeLong J, Murakami T, Yazaki P, Hoffman R, Bouvet M . Near-infrared-conjugated humanized anti-carcinoembryonic antigen antibody targets colon cancer in an orthotopic nude-mouse model. J Surg Res. 2017; 218:139-143. PMC: 5650098. DOI: 10.1016/j.jss.2017.05.069. View

2.
Jang E, Dong Kim D, Cho C . Value and interpretation of resection margin after a colonoscopic polypectomy for malignant polyps. J Korean Soc Coloproctol. 2011; 27(4):194-201. PMC: 3180600. DOI: 10.3393/jksc.2011.27.4.194. View

3.
Maawy A, Hiroshima Y, Zhang Y, Heim R, Makings L, Garcia-Guzman M . Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of pancreatic cancer. PLoS One. 2015; 10(3):e0121989. PMC: 4370703. DOI: 10.1371/journal.pone.0121989. View

4.
Amri R, Bordeianou L, Sylla P, Berger D . Association of Radial Margin Positivity With Colon Cancer. JAMA Surg. 2015; 150(9):890-8. DOI: 10.1001/jamasurg.2015.1525. View

5.
Ogata F, Nagaya T, Nakamura Y, Sato K, Okuyama S, Maruoka Y . Near-infrared photoimmunotherapy: a comparison of light dosing schedules. Oncotarget. 2017; 8(21):35069-35075. PMC: 5471035. DOI: 10.18632/oncotarget.17047. View